HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterates a Neutral rating on Terns Pharma (NASDAQ:TERN) and maintains an $11 price target.
May 19, 2023 | 10:14 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Neutral rating on Terns Pharma (NASDAQ:TERN) and maintains an $11 price target.
The news of HC Wainwright & Co. analyst reiterating a Neutral rating on Terns Pharma and maintaining an $11 price target is directly related to the company. However, since the rating is neutral, it is not expected to have a significant impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100